# US 2025/0147010 A1 · Detection agent, detection system and method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0147010 A1
- Document ID: US20250147010A1
- Status: Published application
- Kind: A1
- Application number: 18/501,302
- Filed: 2023-11-03
- Published: 2025-05-08
- Earliest claimed: 2023-11-03
- Assignees: National Cheng Kung University
- Applicants: National Cheng Kung University
- Inventors: Guan-da SYU; Tzong-shiann HO; Tien-chun TSAI
- Web page: https://patentgrep.com/patent/US20250147010A1

## CPC

- G01N 33/54326: {Magnetic particles}
- C07K 14/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 33/56983: {Viruses}
- G01N 33/582: {with fluorescent label}
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A detection agent, a detection system, and a method thereof are provided. The detection agent includes magnetic barcode beads. Each of the magnetic barcode beads has different two-dimensional edge and is conjugated with a corresponding protein. The protein includes a receptor binding domain of a spike protein or a nucleocapsid protein from a virus or a variant of the virus. The detection system includes the detection agent and a barcode bead fluorescence reader to read a fluorescence signal generated by each of the magnetic barcode beads. The method includes the steps of adding a serum of the subject to the detection agent followed by adding a fluorescently labeled anti-human immunoglobulin antibody and reading a fluorescence signal generated by each of the magnetic barcode beads and discriminating each of the magnetic barcode beads by the barcode bead fluorescence reader to quantify the anti-human immunoglobulin antibody.

## Claims

### Claim 1

A detection agent for profiling a humoral response in a subject, comprising magnetic barcode beads, wherein each of the magnetic barcode beads has different two-dimensional edge and each of the magnetic barcode beads is conjugated with a corresponding protein;
wherein the protein comprises a receptor binding domain of a spike protein or a nucleocapsid protein from a virus or a variant of the virus;
wherein the receptor binding domain of the spike protein of the virus comprises an amino acid sequence of SEQ ID NO: 1;
the receptor binding domain of the spike protein of the variant of the virus comprises an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.

### Claim 2 (depends on 1)

The detection agent according to claim 1, wherein the virus comprises wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, and the variant of the virus comprises SARS-CoV-2 B.1.1.7 variant, SARS-CoV-2 B.1.351 variant, SARS-CoV-2 P1 variant, SARS-CoV-2 B.1.617.2 variant, SARS-CoV-2 B.1.1.529 variant, SARS-CoV-2 BA.2.12.2 variant, SARS-CoV-2 BA.4 variant, or SARS-CoV-2 BA.5 variant.

### Claim 3 (depends on 1)

The detection agent according to claim 1, wherein the nucleocapsid protein of the virus has an amino acid sequence of SEQ ID NO: 10.

### Claim 4 (depends on 1)

The detection agent according to claim 1, wherein the nucleocapsid protein of the variant of the virus has an amino acid sequence of SEQ ID NO: 11.

### Claim 5 (depends on 1)

A detection system for profiling a humoral response in a subject, comprising a detection agent of claim 1 and a barcode bead fluorescence reader, wherein the barcode bead fluorescence reader reads a fluorescence signal generated by each of the magnetic barcode beads.

### Claim 6 (depends on 5)

The detection system according to claim 5, wherein the barcode bead fluorescence reader discriminates each of the magnetic barcode beads by a visible light.

### Claim 7 (depends on 6)

The detection system according to claim 6, wherein the visible light comprises a light-emitting diode.

### Claim 8 (depends on 1)

A method for profiling a humoral response in a subject, comprising the steps of:
providing a detection agent of claim 1;
adding a blocking reagent to the detection agent for reaction;
providing a serum of the subject, adding the serum to the detection agent for reaction, and then washing;
providing a fluorescently labeled anti-human immunoglobulin antibody, adding the fluorescently labeled anti-human immunoglobulin antibody to the detection agent, and reacting followed by washing; and
reading a fluorescence signal generated by each of the magnetic barcode beads and discriminating each of the magnetic barcode beads by a barcode bead fluorescence reader to quantify the anti-human immunoglobulin antibody.

### Claim 9 (depends on 8)

The method according to claim 8, wherein each of the magnetic barcode beads is discriminated by a visible light.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the visible light comprises a light-emitting diode.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the serum incubates with the detection agent for 50 to 70 minutes.

### Claim 12 (depends on 8)

The method according to claim 8, wherein the fluorescently labeled anti-human immunoglobulin antibody incubates with the detection agent for 50 to 70 minutes.

### Claim 13 (depends on 8)

The method according to claim 8, wherein the humoral response is used to evaluate protection ability of a COVID-19 vaccine against wild-type SARS-CoV-2 or SARS-CoV-2 variant.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the SARS-CoV-2 variant comprises SARS-CoV-2 B.1.1.7 variant, SARS-CoV-2 B.1.351 variant, SARS-CoV-2 P1 variant, SARS-CoV-2 B.1.617.2 variant, SARS-CoV-2 B.1.1.529 variant, SARS-CoV-2 BA.2.12.2 variant, SARS-CoV-2 BA.4 variant, and SARS-CoV-2 BA.5 variant.

### Claim 15 (depends on 8)

The method according to claim 8, wherein the humoral response is used to classify healthy subjects and COVID-19 patients with mild/moderate, severe, and critical COVID-19.

### Claim 16 (depends on 8)

The method according to claim 8, wherein the humoral response is used to distinguish the subject vaccinated with a COVID-19 vaccine from the subject infected with COVID-19.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the COVID-19 vaccine comprises mRNA-1273 vaccine or AZD1222 vaccine.

### Claim 18 (depends on 8)

The method according to claim 8, wherein a fluorescence used for the fluorescently labeled anti-human immunoglobulin antibody comprises cyanine dye Cy3 or cyanine dye Cy5.
